• Capricor Therapeutics (CAPR) Upgraded at Zacks Investment Research

    Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a sell rating to a hold rating in a report released on …

    Read More
  • 0 0